Adult stem cell company, Mesoblast Limited (ASX: MSB)(USOTC: MBLTY), announced today that it was very well resourced to strategically expand its clinical programs in bone and cartilage repair, and to execute on its commercial objectives.
The Directors of Solagran Limited (ASX: SLA) are pleased to announce the achievement of the last significant milestone in the process of obtaining Manufacturing Licences for both the prescription pharmaceutical Ropren and its active ingredient Bioeffective R.
Medical Therapies Limited (ASX: MTY), today announced that it has completed its 'first-in-human' clinical trial of Cuprindo(tm) to determine its safety, tolerability and systemic absorption characteristics. The Phase 1 trial was conducted using a topical suppository formulation in preparation for a planned efficacy study in proctitis patients.
The Directors of Solagran Limited (ASX: SLA) are pleased to provide a summary of the results of the Ropren clinical trials conducted at the Skvortsova-Stepanova psychiatric hospital in 2006-07 with serious and critically ill, drug addicted chronic alcoholics. These very challenging trials constitute a key element in Solagran's ongoing research effort in both Australia and Russia to demonstrate the multi-faceted nature of Ropren and specifically its efficacy in the prevention and treatment of a range of neurodegenerative disorders.
Australia's adult stem cell company, Mesoblast Limited (ASX: MSB)(USOTC:MBLTY), today announced highly successful results from its clinical trial at The Royal Melbourne Hospital in 10 patients suffering from non-healing, long bone fractures of the legs.
Biota Holdings Limited (ASX: BTA) today announced that its long acting neuraminidase inhibitor (LANI), CS8958, an antiviral influenza treatment, has completed enrolment for its Phase II clinical study in Japan. The Phase II trial commencement was advised in an ASX Release on 22 November 2007.
Biomedical company, Tissue Therapies Limited (ASX: TIS) today announced that formal approval has been received from the Trafalgar Ethics Board in Toronto to proceed with the human clinical trial of VitroGro for the treatment of diabetic and venous ulcers scheduled to begin later this month.
